{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:26:17Z","timestamp":1787635577612,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JJ30790"],"award-info":[{"award-number":["2022JJ30790"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30713"],"award-info":[{"award-number":["2023JJ30713"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ3037"],"award-info":[{"award-number":["2024JJ3037"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2023XQLH180"],"award-info":[{"award-number":["2023XQLH180"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370149"],"award-info":[{"award-number":["82370149"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303573"],"award-info":[{"award-number":["82303573"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bcp.2024.116717","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T02:54:28Z","timestamp":1734144868000},"page":"116717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The function and mechanism of clinical trial agent CPI-613 in multiple myeloma"],"prefix":"10.1016","volume":"232","author":[{"given":"Haiqin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116717_b0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.bcp.2024.116717_b0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13046-021-02185-1","article-title":"Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer","volume":"40","author":"Ghamlouch","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116717_b0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bcp.2024.116717_b0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2024.116717_b0025","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1002\/jcp.29726","article-title":"Roles of noncoding RNAs in drug resistance in multiple myeloma","volume":"235","author":"Li","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2024.116717_b0030","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.16569","article-title":"The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells","volume":"190","author":"Wu","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2024.116717_b0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2020.11.020","article-title":"Reductive TCA cycle metabolism fuels glutamine and glucose-stimulated insulin secretion","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2024.116717_b0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-022-04475-w","article-title":"A non-canonical tricarboxylic acid cycle underlies cellular identity","volume":"603","author":"Arnold","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116717_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007146","article-title":"Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2024.116717_b0050","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116717_b0055","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00109-011-0785-8","article-title":"Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo","volume":"89","author":"Zachar","year":"2011","journal-title":"J. Mol. Med. (Berl)."},{"key":"10.1016\/j.bcp.2024.116717_b0060","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1158\/1078-0432.CCR-17-2282","article-title":"A phase I study of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia","volume":"24","author":"Pardee","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116717_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164244","article-title":"A phase II clinical trial of CPI-613 in patients with relapsed or refractory small cell lung carcinoma","volume":"11","author":"Lycan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116717_b0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1470-2045(17)30314-5","article-title":"Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial","volume":"18","author":"Alistar","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116717_b0075","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1038\/s41467-022-29039-4","article-title":"Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia","volume":"13","author":"Anderson","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116717_b0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-020-01579-x","article-title":"CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling","volume":"39","author":"Gao","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116717_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s13046-021-02207-y","article-title":"Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer","volume":"40","author":"Lang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2024.116717_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007146","article-title":"Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2024.116717_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: challenges encountered and future options for better treatment","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116717_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2024.116717_b0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2024.116717_b0110","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","article-title":"Promises and challenges of smac mimetics as cancer therapeutics","volume":"21","author":"Fulda","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116717_b0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.bcp.2024.116717_b0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/biom9080356","article-title":"Insights on the use of \u03b1-lipoic acid for therapeutic purposes","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2024.116717_b0125","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1074\/jbc.TM117.000259","article-title":"Lipoic acid metabolism and mitochondrial redox regulation","volume":"293","author":"Solmonson","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116717_b0130","article-title":"Lipoic acid a multi-level molecular inhibitor of tumorigenesis","volume":"1873","author":"Farhat","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2024.116717_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111678","article-title":"The metabolic inhibitor CPI-613 negates treatment enrichment of ovarian cancer stem cells","volume":"11","author":"Bellio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2024.116717_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198940","article-title":"Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma","volume":"13","author":"Egawa","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116717_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110048","article-title":"Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways","volume":"126","author":"Xu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116717_b0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2024.116717_b0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116717_b0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2024.116717_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116717_b0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-21-1069","article-title":"Perspectives on drug development in multiple myeloma-looking forward to 2025","volume":"28","author":"Voorhees","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116717_b0175","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1878-0261.13191","article-title":"Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically","volume":"16","author":"Giliberto","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2024.116717_b0180","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2217\/fon-2019-0209","article-title":"A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas","volume":"15","author":"Philip","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2024.116717_b0185","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2217\/fon-2019-0201","article-title":"Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed\/refractory acute myeloid leukemia: ARMADA 2000 Phase III study","volume":"15","author":"Pardee","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2024.116717_b0190","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1535-7163.MCT-21-0393","article-title":"The mitochondrial disruptor devimistat (CPI-613) synergizes with genotoxic anticancer drugs in colorectal cancer therapy in a bim-dependent manner","volume":"21","author":"Arnold","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2024.116717_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1155621","article-title":"Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment","volume":"13","author":"Matamala Montoya","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116717_b0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1039\/D1MO00106J","article-title":"Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma","volume":"18","author":"Zaal","year":"2022","journal-title":"Mol. Omics"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224007184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224007184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:11:19Z","timestamp":1738818679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224007184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"alternative-id":["S0006295224007184"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116717","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The function and mechanism of clinical trial agent CPI-613 in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116717"}}